A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if administered later in the third trimester.
- Nearly 85% coverage when immunised four weeks before birth
- Maternal antibodies transferred through placenta safeguard newborns from day one
- Protection possible with 2-week gap before early delivery
- Vaccination in third trimester still provides significant infant protection
Persuasive evidence from recent research
The performance of the pregnancy RSV vaccine has been established through a thorough investigation conducted across England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that six-month timeframe, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation gives healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across different groups and contexts.
The results reveal a compelling picture of the vaccine’s ability to protect. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast highlights the vaccine’s essential role in reducing the risk of serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a major public health success, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Study methodology and scope
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospitalisations. The sizeable sample and thorough nature of the data collection ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology assessed practical outcomes rather than laboratory-based settings, providing real-world data of how the vaccine works when delivered across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its hazards
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe adequately. Parents often witness their babies fighting for breath, their chests rising whilst they attempt to draw enough air into their compromised lungs. Whilst most newborns recover with palliative treatment, a small but significant proportion perish from RSV-related complications yearly, making immunisation programmes a critical public health imperative for defending the most vulnerable and youngest people in our communities.
- RSV triggers lung inflammation, leading to serious respiratory problems in infants
- Nearly 50% of newborns contract the infection during their first few months alive
- Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
- More than 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of infants die from RSV related complications annually in the UK
Take-up rates and expert recommendations
Since the RSV vaccine programme launched in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery offers approximately 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies transferred to their babies through the placenta.
The communication from health authorities remains clear: pregnant women ought to prioritise getting vaccinated during their final three months, even if circumstances mean they cannot receive the jab at the best timing. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach recognises the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These regional differences demonstrate differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to engage with women during pregnancy
- Inconsistencies across regions in vaccine uptake rates in different parts of England demand focused enhancement
- Local healthcare systems tailoring initiatives to meet local requirements and situations
Practical implications and parent viewpoints
The vaccine’s outstanding effectiveness translates into tangible benefits for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this preventative solution, the 80% decrease in admissions means thousands of infants shielded from critical disease. Parents no longer face the distressing scenario of watching their newborns struggle for breath or difficulty feeding, symptoms that define severe RSV infections. The vaccine has markedly changed the terrain of neonatal respiratory health, offering expectant mothers a active means to protect their most vulnerable children during those critical early months.
For families like that of Malachi, whose severe RSV infection led to profound brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s advocacy for the jab highlights the profound consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women navigating their late pregnancy, transforming what was once an inevitable seasonal threat into a manageable risk.